Study | Sequence generation | Allocation concealment | Blinding | Adequate handling of incomplete outcome data | Total drop out from drug assignment | No selective reporting | Groups comparable at baseline | Adequate power | Funder |
---|---|---|---|---|---|---|---|---|---|
Dapagliflozin | |||||||||
Bailey et al8 | Yes | Yes | Yes (double blind) | Yes—last observation carried forward | 12% | Yes | Yes | Yes—0.5% HbA1c difference detectable | Astra-Zeneca and Bristol-Myers-Squibb |
Bolinder et al9/Ljunggren et al10 | Yes | Yes | Yes (double blind) | Yes—last observation carried forward | 7.1% | Yes | Yes | Unclear for primary endpoint, 2% BMD difference detectable | Astra-Zeneca and Bristol-Myers-Squibb |
Nauck et al11 | Yes | Yes | Yes (double blind and double dummy) | Yes—last observation carried forward | 22.1% | Yes | Yes | Yes—0.35% HbA1c difference detectable | Astra-Zeneca and Bristol-Myers-Squibb |
Rosenstock et al12 | Not reported | Not reported | Yes (double blind) | Not reported | 8% at 24 weeks, 19% at 48 weeks | Yes | Unclear | Not reported | Astra-Zeneca and Bristol-Myers-Squibb |
Strojek et al13 | Yes | Yes | Yes (double blind and double dummy) | Yes—last observation carried forward | 8.5% | Yes | Yes | Yes—0.5% HbA1c difference detectable | Astra-Zeneca and Bristol-Myers-Squibb |
Wilding et al14 | Not reported | Not reported | Yes (single blind during lead in, double blind during study) | Yes—last observation carried forward | 7% | Yes | Partially; matched for patient demographics, not for prior medications | Yes—0.5% HbA1c difference detectable | Astra-Zeneca and Bristol-Myers-Squibb |
Wilding et al15 | Yes | Yes | Yes (double blind and double dummy) | Yes—last observation carried forward | 11% at 24 weeks, 15.5% at 48 weeks | Yes | Yes | Yes—0.5% HbA1c difference detectable | Astra-Zeneca and Bristol-Myers-Squibb |
Canagliflozin | |||||||||
Rosenstock et al16 | Not reported | Not reported | Yes (double blind) | Yes—last observation carried forward | 10.9% | Yes | Yes | Yes—0.55% HbA1c difference detectable | Janssen Global Services |
BMD, bone mineral density.